Depression following the initiation of glucagon‐like‐peptide‐1 receptor agonist therapy: A multinational self‐controlled case series study

Documenti analoghi

• Increased risk of hypereosinophilia following initiation of glucagon‐like peptide 1 receptor agonist: A symmetry analysis using the Danish health registries
  di: Martin Torp Rahbek, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 agonists for treating substance use disorders: ready for clinical use?
  di: Grace Meulman, et al.
  Pubblicazione: (2026)
• Iatrogenic botulism following cosmetic botulinum toxin injection treated with delayed antitoxin therapy
  di: Samuel Easey, et al.
  Pubblicazione: (2026)
• Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T‐cell therapy for relapsed and refractory lymphoma
  di: Michael Dickinson, et al.
  Pubblicazione: (2025)
• Healthcare burden of public hospital gout admissions in New South Wales, Australia
  di: Wing Wai Tse, et al.
  Pubblicazione: (2024)